TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., August 26, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced unblinded topline results from the first-in-human Phase 1a portion of its ongoing Phase 1a/b clinical trial of TRB-061. Across the single (“SAD”) and multiple […] The post TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis appeared first on TrexBio .